Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the...
Fineline Cube
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting
China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...
BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies
China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million...
Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy
Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced...
Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights
US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...
Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...
R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease
Sichuan R&B Biotech, a China-based biotech firm, announced receiving clinical approval from the US Food...
GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that the New Drug Application (NDA) for...
Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...
Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan
German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...
MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
MSD Appoints Kyle Tattle as President of China Operations
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...
Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received marketing approval from...
MSD and Daiichi Sankyo Withdraw US Filing for Patritumab Deruxtecan in EGFR-Mutated NSCLC
Partners Merck, Sharp & Dohme (MSD; NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced the...
Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...
CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...
Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA
China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...